| Dr Russell Pritchett Hall Iii, MD | |
|
200 Trent Drive, Duke University Medical Center, Durham, NC 27715-3135 | |
| (919) 684-3110 | |
| (919) 684-3002 |
| Full Name | Dr Russell Pritchett Hall Iii |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 49 Years |
| Location | 200 Trent Drive, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205923042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 27920 (North Carolina) | Primary |
| 207NI0002X | Dermatology - Clinical & Laboratory Dermatological Immunology | 27920 (North Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Experts continue to analyze the potential meanings and impacts of a federal judge's ruling earlier this week that the health law is unconstitutional and states find themselves in the hotseat as they make plans to move forward or stall their implementation progress.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.
The Faculty of Medicine and Dentistry of the Universitat de València participates in a pioneering research to advance the prevention of lung damage when providing mechanical ventilation in operations that require general anaesthesia.
A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.
Amidst the Ebola outbreak and subsequent research efforts, Atlanta-based Intellimedix is bringing a new approach to the table. Classical methods of drug development involve performing many experiments only to identify new molecules with a few desired effects.
› Verified 3 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Experts continue to analyze the potential meanings and impacts of a federal judge's ruling earlier this week that the health law is unconstitutional and states find themselves in the hotseat as they make plans to move forward or stall their implementation progress.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.
The Faculty of Medicine and Dentistry of the Universitat de València participates in a pioneering research to advance the prevention of lung damage when providing mechanical ventilation in operations that require general anaesthesia.
A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.
Amidst the Ebola outbreak and subsequent research efforts, Atlanta-based Intellimedix is bringing a new approach to the table. Classical methods of drug development involve performing many experiments only to identify new molecules with a few desired effects.
› Verified 3 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Experts continue to analyze the potential meanings and impacts of a federal judge's ruling earlier this week that the health law is unconstitutional and states find themselves in the hotseat as they make plans to move forward or stall their implementation progress.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.
The Faculty of Medicine and Dentistry of the Universitat de València participates in a pioneering research to advance the prevention of lung damage when providing mechanical ventilation in operations that require general anaesthesia.
A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.
Amidst the Ebola outbreak and subsequent research efforts, Atlanta-based Intellimedix is bringing a new approach to the table. Classical methods of drug development involve performing many experiments only to identify new molecules with a few desired effects.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Russell Pritchett Hall Iii, MD Po Box 3135, Duke University Medical Center, Durham, NC 27715-3135 Ph: (919) 684-3110 | Dr Russell Pritchett Hall Iii, MD 200 Trent Drive, Duke University Medical Center, Durham, NC 27715-3135 Ph: (919) 684-3110 |
News Archive
Experts continue to analyze the potential meanings and impacts of a federal judge's ruling earlier this week that the health law is unconstitutional and states find themselves in the hotseat as they make plans to move forward or stall their implementation progress.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.
The Faculty of Medicine and Dentistry of the Universitat de València participates in a pioneering research to advance the prevention of lung damage when providing mechanical ventilation in operations that require general anaesthesia.
A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.
Amidst the Ebola outbreak and subsequent research efforts, Atlanta-based Intellimedix is bringing a new approach to the table. Classical methods of drug development involve performing many experiments only to identify new molecules with a few desired effects.
› Verified 3 days ago
John F Carr, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4012 Colville Rd, Durham, NC 27707 Phone: 919-489-1826 | |
Dr. John Carroll Murray, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Box 2907 Div Derm Duke Univ Med Center, Durham, NC 27710 Phone: 919-684-2393 Fax: 919-684-6505 | |
Brooke A Jackson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 245 E Nc Highway 54, Suite 202, Durham, NC 27713 Phone: 919-294-9440 Fax: 919-237-3899 | |
Dr. Michelle Bernadette Pavlis, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Suite 210, Durham, NC 27707 Phone: 919-684-8111 | |
Dr. Sabrina Michelle Shearer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Durham, NC 27707 Phone: 919-401-3376 Fax: 919-401-0378 | |
Dr. Lawrence Etter, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3008 Pickett Rd, Durham, NC 27705 Phone: 919-286-7903 Fax: 919-286-7151 | |
Elizabeth L. West, P.A. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-684-8111 |